Muss H B, Blessing J A, Hatch K D, Soper J T, Webster K D, Kemp G M
Department of Medicine, Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, North Carolina.
Am J Clin Oncol. 1990 Feb;13(1):61-3.
Thirty-three patients with advanced or metastatic endometrial carcinoma were entered in a Phase II trial utilizing methotrexate, 40 mg/m2 intravenously on a weekly basis. Almost all patients had prior total abdominal hysterectomy and almost two-thirds prior pelvic irradiation. No patient had prior chemotherapy. There was one complete and one partial response, for a complete and partial response rate of 6% (95% confidence intervals for a response of 1.7 to 19.6%). Toxicity was mild, with major adverse effects being nausea and vomiting and myelosuppression. One death may have been drug related. Methotrexate displays minimal clinical activity in patients with advanced or recurrent endometrial carcinoma who have received no prior chemotherapy.
